The Latest Cardiac and Vascular News
In non-dialysis and dialysis-dependent CKD patients, Major Adverse Cardiovascular Event (MACE) and MACE+ incidence rates were lowest when patients achieved hemoglobin levels ≥ 10 g/dL Two analyses of pooled data from the roxadustat global Phase 3 development program to be presented during the American Society […]
A new study has found females and minorities have a greater risk of restenosis and subsequent MACE than “white” men after receiving everolimus-eluting stent implantation. The Study Setup A cohort study that pulled thousands of patients from both the PLATINUM Diversity and […]
CALGARY, July 10, 2017 /PRNewswire/ – Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) today announced that the first patient has been randomized in Taiwan in the Phase 3 BETonMACE clinical trial with lead drug apabetalone intended for high-risk patients with cardiovascular disease (“CVD”) and […]
By Ken Dropiewski Lipid-rich plaque in non-culprit lesions has long been associated with subsequent cardiac events. Unlike culprit lesions, known to be the cause of AMI, non-culprit lesions including those with a core of lipid-rich plaque are often left untreated […]
